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Sirtuin-1 (SIRT1) is a longevity factor in mammals initiating the cell survival mechanisms, and preventing
ischemic injury in heart. In the etiopathogenesis of heart failure (HF), impairment in cardiomyocyte
survival is a notable factor. Oxidative stress comprises a critical impact on cardiomyocyte lifespan in HF.
The aim of the present study was to investigate SIRT1 expression in patients with compensated (cHF) and
decompensated HF (dHF), and its correlation with oxidative stress. SIRT1 expression in peripheral leu-
kocytes was examined using quantitative RT-PCR in 163 HF patients and 84 controls. Serum total oxidant
status (TOS) and total antioxidant status (TAS) were measured via colorimetric assays, and oxidative
stress index (OSI) was calculated. Lipid parameters were also determined by routine laboratory methods.
SIRT1 mRNA expression was signiﬁcantly downregulated in HF with more robust decrease in dHF
(p¼0.002, control vs cHF; po0.001, control vs dHF). Markedly increased oxidative stress deﬁned as
elevated TOS, OSI and low TAS levels were detected in HF patients comparing with the controls (TAS;
p¼0.010, control vs cHF, p¼0.045 control vs dHF, TOS; p¼0.004 control vs cHF; po0.001 control vs dHF,
OSI; po0.001 for both comparisons, respectively). With SIRT1 expression levels, TAS, TOS, OSI, and high
density lipoprotein levels in cHF and dHF were determined correlated. SIRT1 expression were sig-
niﬁcantly reduced in both HF subtypes, particularly in dHF. SIRT1 expression was correlated with the
oxidant levels and antioxidant capacity. Data suggest that SIRT1 may have a signiﬁcant contribution in
regulation of oxidant/antioxidant balance in HF etiology and compensation status.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sirtuin family comprising of a speciﬁc group of highly con-
served, functional histone deacetylases has indisputable im-
portance in many critical pathways in living organisms. Among the
total of seven members in mammals, Sirtuin-1 (SIRT1; silent
mating type information regulation two homolog-1) gene encodes
the largest member of sirtuin family proteins in human, SIRT1
enzyme, sharing the closest homology with yeast silent informa-
tion regulator 2 (Sir2) [1]. SIRT1 is a NADþ -dependent class IIIB.V. This is an open access article u
kafa).histone/protein deacetylases, and is suggested to ensure the pro-
tection of chromatin structure [2]. Actual roles of human sirtuins
have not yet been fully documented, but functions of their yeast
homolog suggest their importance in cell biology. SIRT1 demon-
strates crucial functions in wide-ranging cellular processes in-
cluding cell survival, apoptotic pathways, oxidative stress and
regulation of gene expression [2–4]. SIRT1 gene product mediates
cellular metabolic functions, and serves as an important regulator
of cellular response to stress conditions through mediating anti-
oxidant mechanisms [5,6]. In heart, SIRT1 is a longevity factor
protecting cells against apoptosis, and mediating survival of car-
diac myocytes under in vitro stress conditions [3,4].
Heart failure (HF) is a major cardiovascular disease character-
ized with a progressive decline in cardiac functions. This conditionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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remarkable mortality and morbidity worldwide. Main etiopatho-
genetic factors responsible for the development of HF are varying
in a range between hemodynamic/ischemic factors to some ge-
netic mutations [7]. It has been well documented that many of
those underlining etiologic factors involve redox imbalance at
their background, and oxidative stress increased in HF [8,9]. Oxi-
dative stress is a well-established phenomenon participating in
numerous diseases and complications in the organ systems, and
the cardiovascular system is not an exception [10].
Based on the symptoms and physical examination, HF is di-
vided into two main categories: compensated HF (cHF) and de-
compensated HF (dHF). In the literature, more evidence is required
to better understand the nature of those two conditions to develop
better therapeutic approaches. In patients with HF having multi-
factorial causes in the etiology, the role of SIRT1 gene has not been
clearly documented to date. It is important to determine expres-
sion level of SIRT1 in patients with HF, and verify its possible
correlation with oxidative stress. Thus, the current study aimed to
investigate differences, if any, between cHF and dHF with a closer
attention to the redox capacity and determine SIRT1 gene ex-
pression levels in patients with either cHF or dHF, and to show its
correlation with oxidative stress.2. Materials and methods
2.1. Subjects
One hundred and sixty-three patients with HF and 84 sex- and
age-matched healthy controls enrolled to the study were divided
into 3 categories as cHF, dHF and control groups. The patients were
chosen among the ones applied to the cardiology clinics at Harran
University Hospital, Ahmet Inan Education and Research Hospital
with cardiac failure symptoms, diagnosed with acute dHF and
hospitalized at coronary intensive care unit or diagnosed with cHF
with no hospitalization requirement within the last month. The
study was planned and performed according to the local and in-
ternational ethical criteria, and was approved by the Institutional
Review Board of Harran University School of Medicine on January
13th, 2014. Informed consent was obtained from all patients and
controls who participated to the study. The ﬁrst group consisted of
84 patients with cHF with ejection fraction (EF) o40%, who came
to the cardiology clinics for routine monitorization, with no acute
coronary event or not required hospitalization for decompensation
of failing heart within the last month. The second group, diag-
nosed with dHF, consisted of 79 patients having EF o40%, and
hospitalized at coronary intensive care unit. The last group was
control formed by sex- and age-matched 84 healthy volunteers
with EF Z50%. Exclusion criteria included a hospitalization within
the last month due to acute coronary syndromes or decom-
pensation for the patients with HF, having a neurodegenerative
disease with decreased SIRT1 expression; having EF lower than
50% despite no diagnosis with HF and a critical infection history
within 1 month.
2.2. Blood samples, serum and leukocyte isolation
Nine ml blood was drawn by venipuncture at the antecubital
vein from the patients and controls, and collected into EDTA tubes
(5 ml) and standard blood collection tubes (4 ml) separately for
leukocyte isolation and analysis of oxidative stress markers. Per-
ipheral blood leukocytes were isolated by density gradient cen-
trifugation within the ﬁrst 2 h of collection and stored at 80 °C
until analysis. For serum isolation, following 1 h of incubation at
room temperature, blood samples were centrifuged at 700 g for15 min, and sera samples were collected and stored at 80 °C
until analysis.
2.3. Real-Time quantitative PCR (RT-qPCR)
RNA was obtained from blood samples of patients and controls.
Isolation of RNA from blood was performed using QIAamp RNA
Blood Mini Kit (Qiagen GmbH, Hilden, Germany). Total RNA quality
and quantity were determined using Epoch Micro-Volume Spec-
trophotometer System (BioTek, Winooski, United States). cDNA
synthesis from total RNA was performed using RT2 First Strand Kit
(Qiagen,).
Commercially available, ready-to-use primers for SIRT1 (catalog
number: PPH02188A-200) and housekeeping gene β-actin (ACTB;
catalog number: PPH00073G-200) were purchased (SA-
Biosciences, Qiagen, Germany). cDNA was ampliﬁed using RT²
SYBR Green ROX FAST Mastermix (Qiagen GmbH, Hilden, Ger-
many) with primer pairs for SIRT1 and β-actin (SABiosciences).
qPCR was performed using a Rotor Gene 6000 Real-Time PCR
Machine (Qiagen GmbH, Hilden, Germany). The ampliﬁcation
conditions were as follows: a 15 min preincubation at 95 °C fol-
lowed by 40 cycles of 15 s at 95 °C and one minute at 60 °C. SIRT1
expression levels were normalized to the corresponding β-actin
gene expression levels, and calculated relative to the mean level in
those acquired from the healthy controls by the comparative
2ΔΔCT method [11].
2.4. Measurement of TAS, TOS and calculation of OSI
Serum TAS and TOS levels were determined using commer-
cially available kits (Rel Assay Diagnostics; Mega Tıp, Gaziantep,
Turkey), and Oxidative Stress Index (OSI) were calculated. Serum
TAS and TOS levels were determined colorimetrically using Spec-
tramax M5 Microplate Reader (MV05047, Molecular Devices in
Sunnyvale, CA) with measurement methods developed by Erel.
Serum TAS levels were presented as μmol Trolox equiv./Liter
[12,13]. Serum TOS assay was calibrated with hydrogen peroxide
(H2O2) and the results were expressed in μmol H2O2 equivalent/l
(μmol H2O2 equiv./Liter) [14]. As a reliable index of oxidative stress
in the body, OSI was calculated as described in literature, and
presented in arbitrary units [15].
2.5. Statistical analyses
Data was analyzed with SPSS 21 statistics software package
(IBM software, Pointe Claire, Quebec, Canada). Distribution pat-
terns of the groups were analyzed using the one-sample Kolmo-
gorov–Smirnov test. Parametric variables between the groups
were compared using one way ANOVA. Multiple comparisons
were analyzed using Bonferroni post hoc test. Sex distribution, the
distribution of individuals with DM, HT and smoking status in
groups were evaluated using Chi-Square test. Covariance between
SIRT1 and interested variables was tested applying Pearson Cor-
relation Coefﬁcient. The results were presented as means7SD if
not stated otherwise. Differences were considered signiﬁcant for
Po0.05.3. Results
A total of 84 patients diagnosed with cHF, 79 patients with dHF
and 84 age- and sex-matched controls were included to the study.
The mean (7SD) ages, sex, waist circumference and calculated
body mass index (BMI) values, along with lipid proﬁles and fasting
glucose levels are presented in Table 1.
Triglyceride levels were signiﬁcantly elevated in the control
Table 1
Demographic and clinical characteristics of the study groups.
Control cHF dHF
n¼84 n¼84 n¼79 P value ANOVA
Age (years) 58.376.8 61.1713.6 61.9711.7 0.090 NS
Male/Female) (n)* 39/45 51/33 39/40 0.148
BMI (kg/m2) 26.972.2 27.174.0 27.474.3 0.686 NS
Waist C. (cm) 97.675.8 99.7711.5 99.2713.8 0.428 NS
Triglyceride (mg/dl) 149.8775.0 145.4767.5 122.2765.5 0.036α
T. Cholesterol (mg/dl) 191.4737.3 175.7738.8 153.5733.9 o0.001β
LDL (mg/dl) 120.7732.5 113.7731.3 95.1727.5 o0.001ω
HDL (mg/dl) 40.779.7 38.579.3 36.5711.9 0.025δ
Hypertension*, n (%) 13(15.5%) 24(28.6%) 21(26.6%) 0.099
DM*, n (%) 8(9.5%) 14(16.7%) 17(21.5%) 0.107
Smoking*n (%) 12(14.3%) 15(17.9%) 18(22.8%) 0.371
* Chi-square test. n, number of individuals; The results are shown as mean7SD. BMI, body mass index; Waist C., waist circumference; T. Cholesterol, total cholesterol;
LDL, low density lipoprotein; HDL, high density lipoprotein; DM, diabetes mellitus; cHF, compensated heart failure; dHF, decompensated heart failure.
α p¼0.047 (Control vs dHF).
β po0.001 (Control vs dHF); p¼0.021 (control vs cHF); p¼0.001 (cHF vs dHF).
ω po0.001 (Control vs dHF); p¼0.001 (cHF vs dHF).
δ p¼0.02 (Control vs dHF).
Fig. 1. Relative SIRT1 mRNA expression levels in the study groups. SIRT1 expression
is reduced in patients with both compensated and decompensated heart failure.
One way ANOVA, 95% conﬁdence interval plots are displayed for the mean SIRT1
expression levels in arbitrary units (AU). * p¼0.002 control vs compensated HF; **
po0.001 control vs decompensated HF.
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signiﬁcantly increased in the control group comparing with both
cHF (p¼0.021) and dHF (po0.001). The same parameter was
signiﬁcantly elevated in patients with dHF in compared to those
with cHF (p¼0.001). Low density lipoprotein (LDL) levels were
signiﬁcantly higher in both control and cHF groups in compared to
dHF group (pr0.001 for both comparisons). For total cholesterol
and LDL, all measurements were within the normal ranges in re-
spect to the laboratory cut-off values. HDL levels were signiﬁcantly
lower in the patients with dHF than those in the control in-
dividuals (p¼0.02). There was no statistically signiﬁcant difference
in waist circumference and BMI among the groups.
The mean serum TAS levels in the control, cHF and dHF groups
were 1.1770.19, 1.0970.14 and 1.1070.21 mmol Trolox Equiv.
Liter1, respectively. Antioxidant levels were signiﬁcantly de-
creased in the patients with HF comparing with the controls,
particularly in the compensated group (p¼0.007). The mean TOS
levels in the control, cHF and dHF are 13.9671.83, 15.5673.55,
15.9673.87 μmol H2O2 Equiv. Liter1, respectively (po0.001).
TOS levels were signiﬁcantly elevated in the HF groups in com-
pared to those in the control group. The mean OSI level calculated
based on TAS and TOS levels, a representation of general redox
status in the body, was signiﬁcantly elevated in both the patients
with compensated and decompensated HF (po0.001) (Table 2).
The expression levels of SIRT1 mRNA were evaluated in per-
ipheral leukocytes harvested from the patients and controls, and
the results were expressed in arbitrary units (AU). The mean SIRT1
mRNA levels were 2.1 (95% CI 1.64–2.52), 1.3 (95% CI 1.07–1.55)Table 2
Oxidative stress parameters of the three groups deﬁned as TAS, TOS and OSI.
Control cHF dHF p value
n¼84 n¼84 n¼79
TAS (mmol trolox equiv.
l1)
1.1770.19 1.0970.14 1.1070.21 0.007*
TOS (μmol
H2O2 equiv. l1)
13.9671.83 15.5673.55 15.9673.87 o0.001ω
OSI [arbitrary units
(AU)]
1.2270.26 1.4570.38 1.5070.47 o0.001ϕ
TAS, total antioxidant status; TOS, total oxidant status; OSI, oxidative stress index.
cHF, compensated heart failure; dHF, decompensated heart failure. The results are
shown as mean7SD.
* p¼0.010 control vs cHF; p¼0.045 control vs dHF.
ω p¼0.004 control vs cHF; po0.001 control vs dHF.
ϕ po0.001 control vs cHF, and control vs dHF.and 1.0 (95% CI 0.81–1.20) AU in the control, cHF and dHF groups,
respectively (Fig. 1). SIRT1 expression was signiﬁcantly attenuated
in HF with a particular decrease in the dHF group without reaching
the signiﬁcance between the HF subgroups (p¼0.002 control vs
cHF; po0.001 control vs dHF).
Pearson’s product moment correlation coefﬁcient was used to
assess a possible covariance between the SIRT1 expression levels
and measured oxidative stress along with the recorded lipid
parameters. For compensated HF, SIRT1 expression was negatively
correlated with OSI (r¼0.348, p¼0.001) and TOS (r¼0.218,
po0.046), and positively correlated with TAS (r¼0.333, p¼0.002).
Additionally, between HDL cholesterol levels and SIRT1, a positive
correlation (r¼0.459, po0.001) was determined within the
compensated HF group.
On the other hand, a similar pattern to above mentioned group
in the correlation study was shown in the dHF group. SIRT1 ex-
pression levels have shown a negative correlation with OSI and
TOS, a positive correlation with TAS and HDL levels within this
group (r¼0.560, po0.001; r¼0.342, p¼0.002, and r¼0.546,
po0.001; r¼0.486, po0.001, respectively).
4. Discussion
SIRT1 is a nuclear protein possessing many key roles in a range
of critical cellular pathways including cellular senescence,
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[3,16]. Studies investigating the functions of SIRT1 in cardiac sys-
tem are increasing, but key functions of SIRT1 expression in heart
have not been clearly shown as of today. It has been reported that
SIRT1 increases tolerance of heart against ischemia and oxidative
stress enhancing endothelial nitric oxide synthase (eNOS) [17].
SIRT1 also functions preventing cardiac hypertrophy and showing
beneﬁcial effects on lipid metabolism via enhancing the activation
of peroxisome proliferator-activated receptor alpha [18]. A study
with transgenic mice has revealed that SIRT1 expression decreased
markedly in ischemic/reperfusion model of heart. It was also
shown in the same transgenic model that moderately increased
expression of SIRT1 in heart prevented programmed cell death and
aging-associated alterations [3]. In the same study, SIRT1 expres-
sion of cardiac myocytes has been found upregulated at the end of
4-week period of pressure load.
On the other hand, SIRT1 expression have been shown down-
regulated in human left ventricle samples harvested from patients
with HF undergoing cardiac transplantation, even though the
sample size was quite low [4]. In patients with severe HF sub-
sequent to dilated cardiomyopathy, cardiac SIRT1 expression has
been determined signiﬁcantly downregulated along with en-
hanced oxidative stress parameters in the harvested tissue sam-
ples [19]. In a recent study involving 48 male participants in-
cluding patients with either acute coronary syndrome or stable
coronary artery disease and the controls, SIRT1 mRNA expression
has been determined signiﬁcantly reduced in peripheral mono-
cytes in the patients [20]. Those reports indicate that SIRT1 ex-
pression in HF is of interest and yet to be clearly documented to
guide in clinical approach. The current study was conducted on a
total of 163 patients with either compensated or decompensated
HF, and SIRT1 transcript expression has been found signiﬁcantly
decreased in harvested leukocytes, especially in patients with dHF
even though the difference did not reach the signiﬁcance. Lower
levels of SIRT1 expression in the cells could be related to increased
susceptibility to cellular oxidative stress based on the literature.
It is now a known fact supported through a number of clinical
and bench studies that oxidative stress increase in HF, not sur-
prisingly, especially in ischemic type of cardiac failure. Enhanced
myocardial oxidative stress, diminished antioxidant levels and
disrupted redox balance have been reported in a rat model of mild
and severe heart failure developed subsequent to myocardial in-
farction, and those changes have shown to be ameliorated at some
degree via supplementation of an antioxidant, vitamin E [21,22].
Similarly, oxidative stress parameters have been found sig-
niﬁcantly increased in an animal model of congestive heart failure
[23]. In patients with chronic ischemic heart failure, Ellidag et al.
reported signiﬁcantly increased oxidative stress index, and atte-
nuated total antioxidant status [24]. Markedly increased oxidative
stress along with inﬂammation has been documented in a clinical
study on patients with severe decompensated congestive HF [25].
In another study conducted on patients with congestive heart
failure at varying degrees, elevated oxidant stress indicated as
increased lipid peroxidation, and decreased antioxidant reserve
were recorded [26].
SIRT1 is a longevity factor with eminent roles in cellular se-
nescence. SIRT1 attenuates oxidative stress and prevent cells
against oxidative damage and eventual apoptosis via several me-
chanisms including the activation of eNOS and Poly (ADP-ribose)
polymerase alpha (PARP α) in heart. To be noted here, a robust
overexpression of PARPα and SIRT1 itself also enhance apoptosis
and negatively affect normal functioning of heart [3,4]. In a ham-
ster model of chronic HF, nuclear SIRT1 expression induced by
resveratrol, a SIRT1 activator, increased Mn-SOD levels in cardio-
myocytes and potentiated resistance against oxidant load, reduced
oxidative stress and suppressed cell death [27]. Additionally,patients with cardiovascular disease carrying certain SIRT1 gene
polymorphisms have been found to be associated with increased
TOS and OSI levels suggesting the protective effect of SIRT1 against
oxidative stress in heart [28]. SIRT1, along with SIRT3, are known
to enhance anti oxidative mechanisms in heart to increase sca-
venger capacity against redox imbalance, and modulate cardio-
myocyte longevity through a number of mechanisms (reviewed in
[27]).
In the present study, our results were in concordance with the
literature conﬁrming that redox balance is disturbed in the pa-
tients with HF, without a signiﬁcant difference between the sub-
groups. We have shown signiﬁcantly enhanced oxidative stress
indicated by elevated TOS and OSI levels and markedly decreased
TAS level in both cHF and dHF groups suggesting an unbalanced
redox status in HF independent of the compensation condition.
Interestingly, we reported here that there was no signiﬁcant dif-
ference in TAS and TOS levels between compensated and decom-
pensated groups although SIRT1 expression levels seemed to be
more severely reduced in patients with dHF. It may be a masked
condition achieved by rush antioxidant therapies along with tight
diet modiﬁcations applied to the patients with dHF during their
stay at the hospital as a supplemental support to the main cardiac
therapies. Unfortunately, there was no available information on
the pharmacological treatments given to the patients along with
the main cardiac therapies.
Studies on SIRT1 and serum lipid proﬁle are relatively new in
literature. It was described in a recent study involving randomly
selected Japanese volunteers that a SIRT1 allele carrying a set of
distinct single nucleotide polymorphisms was found associated
with low LDL and enhanced HDL levels suggesting a link between
SIRT1 expression and serum lipid proﬁle in the same population
[29]. In a study conducted on Ashkenazi Jews, some SIRT1 poly-
morphisms were found associated with HDL and LDL sizes but not
with longevity [30]. Interestingly, in an in vitro study with per-
ipheral monocytes harvested from patients with coronary artery
disease, Breitenstein et al. [20] reported that HDL taken from
healthy subjects induced SIRT1 expression in monocytes more
prominently than HDL taken from patients with cardiac disease
suggesting a signal mediating interaction between HDL and SIRT1,
and disruption of this healthy interaction in patients with cardiac
problems. Based on the output of the present study, serum HDL
levels were signiﬁcantly reduced in the patients with dHF in
compared with the controls. Even though not reaching at the
signiﬁcance, HDL levels were lower in dHF group than those in cHF
group. HDL levels also showed a positive correlation with SIRT1
expression levels in both cHF and dHF groups. A similar results
reported by Breitenstein et al. between HDL levels and SIRT1 ex-
pression in patients with coronary artery disease [20]. Although it
needs more studies to delineate its function, HDL may be an
amelioration factor in the disease course in HF.
Increased LDL and total cholesterol levels detected in control
and cHF groups comparing with the dHF group revealed a com-
plicated outcome, since the data may imply some speciﬁc medical
care given to those patients during their follow-up period, al-
though we did not record any dyslipidemia treatment. Regarding
with serum triglyceride levels, patients with cHF have had higher
levels than those in dHF and control groups. To be noted here, lipid
measurements recorded in the patients and controls during the
study were within the normal ranges according to the clinical data
and laboratory cut-off values. More likely explanation to those
results would be attributed to the tight diet modiﬁcations and
daily life changes suggested to our study patients due to their
health conditions.
In conclusion, we have reported here that the expression levels
of SIRT1 transcript in peripheral blood leukocytes signiﬁcantly
decreased in patients with compensated and decompensated HF,
F. Akkafa et al. / Redox Biology 6 (2015) 169–173 173particularly in decompensated group although the difference did
not reach the signiﬁcance. Redox balanced was disturbed in HF,
and evaluated SIRT1 mRNA levels correlated negatively with OSI
and TOS, and positively with serum TAS and HDL levels in both
patient groups with cHF and dHF. Reduced expression of SIRT1 in
peripheral leukocytes may be associated with the compensation
status of HF since slightly further decrease of SIRT1 expression was
determined in dHF as compared to cHF and controls.Acknowledgments
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